News | January 20, 2015

PotentiaMED Advisor Highlights Problems with Cancer Clinical Trials

Poor representative patient selection, exclusion of mitigating factors among issues to address

January 20, 2015 — The validity of randomized clinical trials in cancer has recently been called into question as many healthcare professionals are decrying the “experimerical” nature of these studies.

Jay F. Piccirillo, M.D., FACS, medical advisor for PotentiaMED, said, “The very nature of these studies is biased because they are often sponsored by pharmaceutical and device companies who have a vested interest in ensuring the studies have a positive outcome.”

 Piccirillo outlines the reasons randomized clinical trials are problematic:

  • Randomized clinical trials enroll younger and less racially diverse patients of the cancer population. “We know that roughly 53 percent of cancer patients are over the age of 65,” said Piccirillo, “Yet less than 33 percent of patients in the study are in this age group. Hence, we are getting data that is based on people who are much younger than the majority of our patients. Additionally, most of the people studied are white, meaning that we don’t have much data on people of color.”
  • Randomized clinical trials don’t consider comorbidity. “We have a saying in cancer treatment: ‘Sicker people die sooner,’” said Piccirillo. “This means that cancer patients with coexisting lung disease, heart disease, diabetes or other illnesses are less likely to improve with treatment and more likely to succumb quicker than cancer patients with less severe comorbidity. However, randomized clinical trials often exclude patients with comorbid ailments and so the results are not applicable to a large number of cancer patients.”
  • Randomized clinical trials don’t consider quality of life. “Randomized clinical trials seek ‘objective’ markers such as survival and tumor recurrence rates,” said Piccirillo, “These are important endpoints, however, patients increasingly also want information on quality of life and this important data simply isn’t available through clinical trials.”
  • Randomized clinical trials aren't publicized equally. “It is an inescapable truth that many of these trials are performed by companies who have a vested interest in the outcome,” said Piccirillo. “As such, they only tend to submit for publication and publicize positive findings. In fact, one study of selective publication bias found that 97 oercent (37 of 38) of positive trials were published while only 33 percent (8 of 24) of negative trials were published. This means that clinicians and patients who review the published medical literature receive a biased impression of treatment effectiveness.

 

“The reality is that only four percent of adults with cancer are involved in randomized clinical trials, yet healthcare professionals are using this information to determine the treatment for the other 96 percent of the population,” said Piccirillo. 

PotentiaMED was founded in 2009 with the goal of collecting and supplying invaluable treatment information for patients, doctors, hospitals, insurance providers, medical technology, and insurance providers. The PotentiaMED database offers patients all the data they need at their fingertips, from life expectancy to side effects to quality of life to future risk.

For more information: www.potentiamed.com

Related Content

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine latera

(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine lateral sampling (requiring dithering); the filled circles show the data that are sampled without dithering.

News | Computed Tomography (CT) | July 24, 2020
July 24, 2020 — A computed tomography (CT) sca
Medical professionals around the world have been feeding lung X-rays into a database since the beginning of the pandemic

Pre-processing results. Image courtesy of Applied Sciences.

News | Coronavirus (COVID-19) | July 22, 2020
July 22, 2020 — Researchers from the Departme
Pioneering study, which included humans, led by Tel Aviv University researchers contradicts widespread conjectures
News | Magnetic Resonance Imaging (MRI) | July 21, 2020
July 21, 2020 — Researchers at Tel Aviv University, led by Prof.

Fig. 1 The basis of high-sensitivity SPION imaging at ultra-low magnetic fields.

(A) Magnetization of 25-nm SPIONs (green), gadolinium CA (Gd-DTPA/Magnevist, blue), and water (red) as a function of magnetic field strength (B0). (B) Magnetization as a function of magnetic field strength (B0) in the ULF (<10 mT) regime for the materials shown in (A). Superparamagnetic materials, such as SPIONs, are highly magnetized even at ULF. Paramagnetic materials, such as CAs based on gadolinium, and body tissues (which typically have diamagnetic susceptibilities close to water) have absolute magnetizations that increase linearly with field strength. Curves in (A) and (B) were reproduced from data in (3253) and reflect the magnetic moment per kilogram of compound. (C) Highly magnetized SPIONs (brown) interact with nearby 1H spins in water, shortening 1H relaxation times, and causing susceptibility-based shifts in Larmor frequency. Image courtesy of Science Advances

News | Magnetic Resonance Imaging (MRI) | July 20, 2020
July 20, 2020 — Lowering the cost of magne...
Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

News | PET Imaging | July 15, 2020
July 15, 2020 — A first-in-human study presented at the Society of...
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Artificial intelligence (AI)-assisted software was used to identify inflammatory tissues in lung and automatically segment inflammatory lesions. Three-dimensional image shows regions of COVID-19 pneumonia in lung through AI postprocessing. Image courtesy of the American Journal of Roentgenology (AJR)

Artificial intelligence (AI)-assisted software was used to identify inflammatory tissues in lung and automatically segment inflammatory lesions. Three-dimensional image shows regions of COVID-19 pneumonia in lung through AI postprocessing. Image courtesy of the American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | July 10, 2020
July 10, 2020 — An open-access Ameri
 Many patients with severe coronavirus disease 2019 (COVID-19) remain unresponsive after surviving critical illness. Investigators led by a team at Massachusetts General Hospital (MGH) now describe a patient with severe COVID-19 who, despite prolonged unresponsiveness and structural brain abnormalities, demonstrated functionally intact brain connections and weeks later he recovered the ability to follow commands

Getty Images

News | Coronavirus (COVID-19) | July 08, 2020
July 8, 2020 — Many patients with severe coronavirus disease 2019 (...